Acute myeloid leukemia (AML) remains a complex challenge. Though many investigational therapies are emerging, the diverse nature of AML demands in-depth clinical investigation to develop effective treatments.
In this article, we examine the current AML landscape, providing research professionals with a data-driven overview of the AML trial space, revealing a robust pipeline across phases and mechanisms, using real-world analytics from Citeline. We will conclude by highlighting Precision for Medicine’s past and current expertise with AML.
Understanding the Acute Myeloid Leukemia Clinical Trial Landscape
Acute Myeloid Leukemia represents a considerable concern in global healthcare. Over 124,000 people diagnosed with AML each year worldwide, the need for effective treatments is clear.
AML Clinical Trials by Status
Looking at Citeline’s Trialtrove, we can see that there are 5,257 trials on record that included participants with AML and of these, around 24% are planned or ongoing.
AML Trials by Status
AML Trials by Start Date
The number of AML trials is growing, with more trials opening every year. Here, we can see planned and ongoing AML trials by start date.
Planned & Ongoing AML Trials by Start Date
AML Trials by Country
The United States is at the forefront of AML trials. Of the more than 5,100 AML trials recorded to date, over 30 percent had at least one site in the United States. However, there are several countries of note in AML research. China figures prominently as does Germany, France, and Italy.
Planned & Ongoing AML Trials by Site Country
AML Trials by Patient Line of Therapy
Planned or ongoing industry sponsored AML trials may be divided into each segment or line of therapy (e.g., first line, second line, third line or greater). Please note that some of these trials may include more than one line of therapy.
| FIRST LINE | SECOND LINE | THIRD LINE OR GREATER |
|---|---|---|
| 169 Trials | 413 Trials | 96 Trials |
AML Trials by Phase
Analysis of trial phase provides a view of therapeutic progress ranging from safety, proof of concept, and efficacy. Most AML trials are in Phases 1 and 2, reflecting a strong early and future pipeline of treatments. Precision specializes in Phase 1/2 trials. Precision’s early phase focus reflects early collaboration with biotech and pharmaceutical firms, demanding specific expertise. Phase 1/2 combination trials often use adaptive designs, demand specific site capabilities, require flexible teams and can be more complex than conventional trial designs.
Planned & Ongoing AML Trials by Phase
Precision’s Expertise in AML Research
Navigating the intricate landscape of AML research requires a partner that not only understands the complexities but also has the expertise to conduct clinical trials. Precision for Medicine stands out having proven itself as a leader in the field.
Over the years, Precision for Medicine has consistently showcased its capabilities, carving out a strong and influential position in AML research. Our success is the result of a sustained commitment to excellence that spans more than a decade, and it’s why our Industry partners choose us trial after trial.
AML Trial Starts
Precision for Medicine has been at the forefront of AML clinical trial execution. Over the past three years, we have embarked on seven new AML trials, each one a testament to our commitment to transforming lives through scientific discovery.
As a premier global precision medicine clinical research organization, we continue to lead the way, partnering with sponsors to test the latest scientific advances in clinical trials.
Precision for Medicine’s AML Trials by Start Date
Precision’s Reach in AML Research
Precision for Medicine’s experience in AML research is not confined to a single geography. While our roots and most of our experience are in the United States, our reach extends far beyond. We have successfully conducted trials in several countries that are at the forefront of AML research. This includes China, Germany, France, Italy, Spain, and the United Kingdom. Our global footprint is a testament to our commitment to be where the research and patients are, ensuring we are at the cutting edge of advancements in AML. At Precision, we are dedicated to transforming lives through scientific discovery, wherever that may take us.
Precision for Medicine’s AML Trials by Site Country
Trials by Phase
Our expertise is particularly pronounced in Phase 1/2 trials, where we have accumulated a wealth of knowledge and experience. Early phase trials assess the safety and dosing of new treatments, and our significant involvement in this area underscores our commitment to pioneering research.
However, our experience is not limited to early phase trials. We also conduct larger, Phase 2 and Phase 3 trials. These trials are instrumental in evaluating the effectiveness of new treatments in larger patient groups and comparing the new treatment to current standard treatments. Our involvement in these later phase trials demonstrates our capacity to manage large-scale studies and our dedication to advancing AML research at all levels and geographies.
Our comprehensive experience across different trial phases enables us to provide a holistic approach to AML research, from early safety assessments to large-scale efficacy studies.
Precision for Medicine’s AML Trials by Phase
Precision’s Experience by Patient Segment
Our experience spans across various patient segments, reflecting our comprehensive focus on AML research.
In the first line of treatment, we have conducted 9 trials, laying the groundwork for initial patient care. Our commitment deepens in the second line, where we have led 21 trials. For those in the third line and beyond, we have initiated 7 trials, demonstrating our dedication to patients with the most advanced disease.
| FIRST LINE | SECOND LINE | THIRD LINE OR GREATER |
|---|---|---|
| 9 Trials | 21 Trials | 7 Trials |
Precision AML Trials by Therapeutic Class
At Precision, our research extends across various therapeutic classes, reflecting the industry’s varied approach to AML therapeutic development.
Precision for Medicine’s AML Trials by Therapeutic Class
Our expertise is particularly notable in the realm of small molecule therapies and antibody-drug conjugates (ADCs). Small molecules, ADCs, and monoclonal antibodies often require biomarker analysis and enrollment of defined patient subsets, which has driven Precision to develop a variety of custom enrollment strategies for these types of clinical trials.
Drug Targets Studied with Precision
Precision for Medicine has studied a wide array of drug targets. Our expertise is particularly notable with CD123, a target that has shown promise in the treatment of AML. However, our experience extends far beyond this single target.
We have conducted research involving numerous other targets, each offering unique potential in diverse AML sub-types.
Precision for Medicine’s AML Trials by Drug Target
Understanding the Precision Difference
Precision for Medicine’s extensive experience in AML research is a testament to our commitment to transforming lives through scientific discovery. We have delved into the specifics of our AML trials, discussing the year, country, patient segment, and phase of each trial. We have also highlighted our work with various drug targets and therapeutic classes.
Learn how Precision is pushing the boundaries of what’s possible in AML research.
